evertex fabrinology limited
TWSE:1470.TW
23.3 (TWD) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 655.221 | 845.152 | 894.789 | 630.757 | 818.166 | 754.462 | 701.061 | 685.778 | 761.731 | 744.311 | 669.101 | 696.712 | 789.031 | 811.037 | 709.451 |
Cost of Revenue
| 525.403 | 670.834 | 703.668 | 517.086 | 603.76 | 586.4 | 550.707 | 531.084 | 594.712 | 584.971 | 575.638 | 629.066 | 684.531 | 686.178 | 591.249 |
Gross Profit
| 129.818 | 174.318 | 191.121 | 113.671 | 214.406 | 168.062 | 150.354 | 154.694 | 167.019 | 159.34 | 93.463 | 67.646 | 104.5 | 124.859 | 118.202 |
Gross Profit Ratio
| 0.198 | 0.206 | 0.214 | 0.18 | 0.262 | 0.223 | 0.214 | 0.226 | 0.219 | 0.214 | 0.14 | 0.097 | 0.132 | 0.154 | 0.167 |
Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
General & Administrative Expenses
| 29.424 | 30.764 | 33.859 | 33.264 | 43.435 | 39.62 | 40.059 | 37.024 | 31.171 | 29.734 | 24.251 | 21.93 | 23.684 | 21.302 | 19.784 |
Selling & Marketing Expenses
| 67.191 | 75.166 | 78.82 | 61.944 | 84.814 | 76.926 | 72.867 | 69.855 | 66.694 | 58.736 | 49.019 | 43.513 | 40.533 | 42.952 | 39.83 |
SG&A
| 96.615 | 105.93 | 112.679 | 95.208 | 128.249 | 116.546 | 112.926 | 106.879 | 97.865 | 88.47 | 73.27 | 65.443 | 64.217 | 64.254 | 59.614 |
Other Expenses
| -95.374 | -19.053 | -1.135 | -0.903 | -0.02 | 6.13 | 7.121 | 1.114 | 3.179 | 5.125 | 5.307 | 3.345 | 2.124 | 4.159 | 3.047 |
Operating Expenses
| 95.374 | 105.93 | 111.544 | 94.305 | 128.229 | 115.675 | 110.946 | 102.487 | 97.43 | 86.56 | 62.012 | 65.443 | 64.217 | 64.254 | 59.614 |
Operating Income
| 34.444 | 50.569 | 79.2 | 41.743 | 94.339 | 52.387 | 39.408 | 52.207 | 69.589 | 72.78 | 31.451 | 2.203 | 40.283 | 60.605 | 58.588 |
Operating Income Ratio
| 0.053 | 0.06 | 0.089 | 0.066 | 0.115 | 0.069 | 0.056 | 0.076 | 0.091 | 0.098 | 0.047 | 0.003 | 0.051 | 0.075 | 0.083 |
Total Other Income Expenses Net
| 22.734 | -0.568 | -0.451 | -0.912 | -0.645 | 8.855 | 9.693 | 4.325 | 5.461 | 7.382 | 5.307 | 15.491 | 10.082 | 10.172 | 3.653 |
Income Before Tax
| 57.178 | 50.001 | 78.749 | 40.831 | 93.694 | 61.242 | 49.101 | 56.532 | 75.05 | 80.162 | 36.758 | 17.694 | 50.365 | 70.777 | 62.241 |
Income Before Tax Ratio
| 0.087 | 0.059 | 0.088 | 0.065 | 0.115 | 0.081 | 0.07 | 0.082 | 0.099 | 0.108 | 0.055 | 0.025 | 0.064 | 0.087 | 0.088 |
Income Tax Expense
| 7.832 | 17.158 | 13.548 | 5.417 | 17.833 | 12.375 | 7.267 | 9.576 | 13.949 | 13.795 | 7.458 | 2.917 | 8.579 | 13.867 | 8.88 |
Net Income
| 49.346 | 32.843 | 65.201 | 35.414 | 75.861 | 48.867 | 41.834 | 46.956 | 61.101 | 66.367 | 29.3 | 14.777 | 41.786 | 56.91 | 53.361 |
Net Income Ratio
| 0.075 | 0.039 | 0.073 | 0.056 | 0.093 | 0.065 | 0.06 | 0.068 | 0.08 | 0.089 | 0.044 | 0.021 | 0.053 | 0.07 | 0.075 |
EPS
| 0.58 | 0.38 | 0.76 | 0.41 | 0.88 | 0.57 | 0.49 | 0.55 | 0.71 | 0.77 | 0.34 | 0.17 | 0.49 | 0.66 | 0.62 |
EPS Diluted
| 0.57 | 0.38 | 0.76 | 0.41 | 0.88 | 0.57 | 0.49 | 0.55 | 0.71 | 0.77 | 0.34 | 0.17 | 0.49 | 0.66 | 0.62 |
EBITDA
| 108.284 | 103.249 | 135.155 | 91.437 | 142.604 | 114.758 | 86.554 | 98.479 | 116.023 | 121.338 | 80.827 | 43.898 | 97.958 | 116.602 | 106.488 |
EBITDA Ratio
| 0.165 | 0.122 | 0.151 | 0.145 | 0.174 | 0.152 | 0.123 | 0.144 | 0.152 | 0.163 | 0.121 | 0.063 | 0.124 | 0.144 | 0.15 |